Skip to content

Clinical trials

Phase 1 Endometrial Neoplasms trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Endometrial Neoplasms Phase: Phase 1 Country / region: China Clear all

18 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20151
20202
20223
20232
20243
20254
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting7
Not yet recruiting3
Unknown status3
Active, not recruiting2
Terminated2
Completed1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Eli Lilly and Company2
BeiGene1
Chinese PLA General Hospital1
Danatlas Pharmaceuticals Co., Ltd1
GlaxoSmithKline1
Haihe Biopharma Co., Ltd.1
Huahui Health1
Multitude Therapeutics Inc.1
Risen (Suzhou) Pharma Tech Co., Ltd.1
Seagen, a wholly owned subsidiary of Pfizer1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Endometrial Neoplasms18
Ovarian Neoplasms9
Breast Neoplasms7
Stomach Neoplasms7
Triple Negative Breast Neoplasms7
Carcinoma, Non-Small-Cell Lung5
Colorectal Neoplasms4
Prostatic Neoplasms4
Squamous Cell Carcinoma of Head and Neck4
Uterine Cervical Neoplasms4

Trials

Showing 1 to 18 of 18. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.